Clik here to view.
Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures...
MONT-SAINT-GUIBERT, Belgium & TOKYO Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced the addition of €7.5 million to its recent €39.7...
View ArticleClik here to view.
シアトル・ジェネティクスと武田薬品がアドセトリス（ブレンツキシマブ・ベドチン）の第3相臨床試験のECHELON-1およびECHELON-2の追加解析データ...
米ワシントン州ボセル & マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Agreement With COFCO Biotechnology Sets Stage for Avivagen to Secure...
OTTAWA, Ontario Avivagen Inc. (TSXV:VIV) (“Avivagen”) has announced that it has entered into an agreement with the research subsidiary of COFCO Biotechnology Co. Ltd. (“COFCO”) pursuant to which...
View ArticleClik here to view.
Sengenics, a Leading Commercial Stage Precision Medicine Focused Company,...
SINGAPORE Sengenics, a leading commercial stage precision medicine focused company, today announced that Dr Arif Anwar, CEO of Sengenics, has been invited to present at the Biotech Showcase™ during...
View ArticleClik here to view.
RAPID AI Enhanced Advanced Medical Imaging for Stroke Now Installed in Vietnam
MENLO PARK, Calif. RAPID, the worldwide leader in advanced imaging for stroke, is now available and installed in Vietnam. The RAPID artificial intelligence framework helps to quantify brain lesions...
View ArticleClik here to view.
山东方坦思宣布与杨森制药达成许可协议将开发抗IL-17A单克隆抗体并使其商业化
2019年12月17日[美国东部时间 (美国商业资讯)– 山东方坦思生制药有限公司（“方坦思”）今日宣布与强生公司旗下的一家杨森制药公司（“杨森”）签订独家许可、开发和商业化协议，在中华人民共和国（“中国”）包括香港特别行政区（“香港”）、澳门特别行政区（“澳门”）、台湾区域（“台湾”） 和韩国开发含有抗IL-17A单克隆抗体的医药产品并使其商业化。...
View ArticleClik here to view.
Shandong Fontacea Announces License Agreement with Janssen to Develop and...
JINAN, Shandong, People’s Republic of China Shandong Fontacea Pharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license, development and commercialization...
View ArticleClik here to view.
Company Profile for Shandong Fontacea Pharmaceutical Co. Ltd.
About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market,...
View ArticleClik here to view.
China’s Center for Drug Evaluation of the National Medical Products...
AUSTIN, Texas The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has released the requirements of clinical trial data submission in the electronic...
View ArticleClik here to view.
Alpha Holdings Sends Open Letter to OncoSec Stockholders
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
HitGen and MTPC Enter Into License Agreement
CHENGDU, China HitGen Inc. (HitGen) announced today that HitGen and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered into a license agreement to develop a novel class of drugs. The licensed...
View ArticleClik here to view.
Konkuk University Research Team Develops a New Alcoholic Fermentation Method
SEOUL, South Korea A research team at Konkuk University in Seoul, South Korea developed a new alcoholic fermentation method using an electrospray cell patterning technology. This press release...
View ArticleClik here to view.
NeuClone Completes Dosing in Phase I Clinical Trial of Stelara®...
SYDNEY NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced successful recruitment...
View ArticleClik here to view.
Alpha Holdings Files Shareholder Presentation on Opposition to Proposed China...
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Vantage 2020 Preview: Strong Sales and Product Launches Set the Stage for...
LONDON & BOSTON & TOKYO Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage...
View ArticleClik here to view.
Exopharm Backs Regulatory Crackdown on Unapproved Exosome Products
MELBOURNE, Australia A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved...
View ArticleClik here to view.
Turnstone Biologics Announces Global Collaboration and License Agreement with...
NEW YORK Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies, today announced a strategic collaboration with Takeda Pharmaceutical Company...
View ArticleClik here to view.
Promega Corporation Enters License Agreement with MilliporeSigma to Access...
MADISON, Wis. Promega Corporation today announced it has signed a license agreement with MilliporeSigma, a leader in genome editing, to access MilliporeSigma’s foundational CRISPR genome-editing...
View ArticleClik here to view.
Boston’s XenoTherapeutics Prepares to Donate Xeno-Skin™ to Burn Victims of...
BOSTON XenoTherapeutics, Inc. a clinical-stage biotechnology company focused on immunogenomic reprogramming of swine organs and tissues for human use, announced their readiness to supply victims of...
View Article